Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Myelodysplastic syndrome (MDS) is a rare disease of the blood, occurring in just four out of every one million children. This rare blood disorder keeps the body from properly producing blood cells and producing enough of them. MDS develops in the bone
marrow, the soft, spongy center of the long bones that produces the three major blood cells. With this disease, the blood cells lose their ability to mature and function properly.
Children with MDS are treated through the Bone Marrow Failure and Myelodysplastic Syndrome Program at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, one of the nation's most experienced, multidisciplinary teams at diagnosing and treating childhood MDS. Dana-Farber/Boston Children's has been designated a "Center of Excellence"
by the MDS Foundation - the only large pediatric center in the country awarded this designation.
FindFind in-depth information about myelodysplastic syndrome (MDS) on the Boston Children's Hospital website, including:
New Patient Appointments